argenx will acquire Forte Biosciences for $2.2 billion, adding the first-in-class anti-CD122 antibody FB102 to its immunology pipeline. The deal, expected to close in Q3 2026, aims to accelerate development for multiple autoimmune diseases and strengthen long-term growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.